Invivogen
Menu

Recombinant Human Fc-hCD70 Fusion Protein

Product Unit size Cat. code Docs. Qty. Price

Fc-hCD70

Soluble human CD70 fused to an IgG1 Fc domain

Show product

50 µg

fc-hcd70
+-
$167
  • About
  • Specifications
  • Contents
  • Details
  • Related products

Soluble human CD70 (CD27L) fused to an IgG1 Fc domain

Potential applications of soluble Fc-hCD70 protein
Potential applications of soluble Fc-hCD70 protein

Protein description

InvivoGen offers Fc-hCD70, a soluble human CD70 (CD27L, TNFSF7) chimera protein generated by fusing the N-terminal extracellular domain of human CD70 (aa 39-193) to the C-terminus of a human IgG1 Fc domain with a TEV (Tobacco Etch Virus) sequence linker.
Fc-hCD70 has been produced in CHO cells and purified by affinity chromatography. It has an apparent molecular weight of ~48 kDa on an SDS‑PAGE gel.

 

CD70 background

CD70 (CD27L, TNFSF7) is a Type II transmembrane protein and a member of the TNFR family known as the ligand for the CD27 receptor on T cells. CD70 is primarily expressed on antigen-presenting cells (APCs).  The CD70-CD27 interaction promotes T cell activation and maturation, in concert with the T cell receptor engagement [1]. The CD27/CD70 axis is thus considered a costimulatory immune checkpoint [2].

More details More details

 

Applications

  • Screening of high-affinity anti-human CD70 monoclonal antibodies by ELISA
  • Screening of anti-human CD27 monoclonal antibodies using competition assays

Quality control

  • Size and purity confirmed by SDS-PAGE
  • Protein validated by ELISA using Anti-hCD70-hIgG1 monoclonal antibody
  • Protein validated by flow cytometry using Jurkat-Lucia™ hCD27 cells
  • Protein potency at triggering intracellular signaling validated using Jurkat-Lucia™ hCD27 cells

 

References

1. Jacobs, J. et al., 2015. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther 155, 1-10.
2. Flieswasser, T. et al., 2022. The CD70-CD70 axis in oncology: the new kids on the block. J Exp Clin Cancer Res 41, 12. 

Figures

Fc-hCD70 analysis by SDS-PAGE
Fc-hCD70 analysis by SDS-PAGE

SDS-PAGE analysis of the Fc-hCD70 protein. 0.5 µg of the fusion protein was loaded on a 12% Mini-PROTEAN® TGX Stain-Free™ Precast Gels (Bio-Rad). Detection was performed as per the manufacturer’s instructions.

Cell surface staining using Fc-hCD70
Cell surface staining using Fc-hCD70

Human CD27 cell surface detection using Fc-hCD70. ~5 x 105 Jurkat-Lucia™ hCD27 cells were incubated with 2 µg of Fc-hCD70 for 30 min at 4°C. Cells were then washed and incubated with 1 µl of mouse anti-human IgG Fc antibody coupled to PE for 30 min at 4°C. Cell surface staining was analyzed by flow cytometry.

ELISA detection of Fc-hCD70
ELISA detection of Fc-hCD70

ELISA detection of Fc-hCD70 with Anti-hCD70-hIgG1 mAb. The Fc-hCD70 fusion protein was performed and coated at 2 µg/ml on ELISA plates overnight. A 3-fold serial dilution of Anti-hCD70-hIgG1 (red curve) or Anti-β-Gal-hIgG1 control mAb (grey curve) was added for the capture step. An HRP-labeled anti-human κ light chain antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride) were used for the detection step. Absorbance was read at 490 nm.

Activation of Jurkat-Lucia™ hCD27 cells using a CD27 agonist
Activation of Jurkat-Lucia™ hCD27 cells using a CD27 agonist

Activation of Jurkat-Lucia™ hCD27 cells. Jurkat-Lucia™ hCD27 cells were incubated with increasing concentrations of recombinant human Fc-CD70 fusion protein for 24 hours. The NF-κB activation in Jurkat-Lucia™ hCD27 cells was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™ 4. Fold responses are shown as mean ± SEM.

Back to the top

Specifications

Protein construction: N-terminal extracellular domain of human CD70 (aa 39-193) with an N-terminal human IgG1 Fc tag 

Accession sequence: NM_001253.1

Species: Human

Source: CHO cells

Tag: N-terminal human IgG1 Fc

Total protein size: 155 a.a (secreted form)

Molecular weight: ~48 kDa (SDS-PAGE)

Purification: Protein G affinity chromatography

Purity: >91% (SDS-PAGE)

Quality control:

  • The protein is validated by ELISA upon incubation with an Anti-hCD70 monoclonal antibody.
  • The protein is validated by flow cytometry using Jurkat-Lucia™ hCD27 cells.
  • The potency of Fc-hCD70 at triggering intracellular signaling is validated using Jurkat-Lucia™ hCD27 cells.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) is confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.
Back to the top

Contents

  • 50 μg of lyophilized Fc-hCD70 protein
  • 1.5 ml of endotoxin-free water

room temperature The product is shipped at room temperature.

store Lyophilized protein should be stored at -20 ̊C.

stability Resuspended protein is stable for up to 1 month when stored at 4°C, and 1 year when stored at -20°C

Avoid repeated freeze-thaw cycles.

Back to the top

Details

The CD27/CD70 immune checkpoint

The CD27–CD70 axis plays an important role in immune regulation and is considered an immune checkpoint (IC)

The cluster of differentiation CD27 is a member of the TNFR (tumor necrosis factor receptor) superfamily. In humans, CD27 is constitutively expressed on most T cells, memory B cells, plasma cells, and Natural Killer cells [1].

The Cluster of Differentiation CD70 (aka CD27L, TNFSF7) is also a member of the TNFR family and is known as the sole ligand for CD27. Expression of CD70 is tightly controlled and induced transiently in antigen-presenting cells (APCs) following stimuli exposure, such as TFN-α, irradiation, or TLR agonists [2, 3]. 

The CD27 and CD70 interaction triggers the TRAF2-TRAF6-NF-kB signaling pathway, and in concert with the T cell receptor (TCR) crosslinking, contributes to efficient T cell activation, proliferation, survival, maturation of effector capacity, and T cell memory [2-4].

 

The CD27/CD70 immune checkpoint in cancer

CD27 is expressed in various types of hematologic cancers. In leukemia, CD27 signaling leads to the induction of different pathways, supporting stemness, tumor cell proliferation, and self-renewal [1]. The efficacy of targeting the CD27/CD70 axis with an agonistic CD27 mAbs was shown in preclinical models of lymphoma, renal cell carcinoma (RCC), breast cancer, and sarcoma [5]. A human mAb directed at CD27 named varlilumab (also CDX-1127, 1F5) has entered clinical trials. It can activate CD27-positive T cells while mediating the killing of CD27-expressing tumor cells [5, 6]. Also, it has successfully completed a phase I/II dose escalation and cohort expansion study (NCT02335918) in combination with nivolumab in different solid malignancies. Further phase I trials with various combinations as well as phase II trials are still ongoing in renal cell carcinoma, squamous cell carcinoma of the head and neck, ovarian and colorectal cancers, and glioblastoma [5].

Constitutive overexpression of CD70 has been described in a range of solid and hematological malignancies, whereby tumor cells have hijacked the CD27-CD70 signaling pathway to facilitate immune evasion in the tumor microenvironment (TME) [7]. They do this by increasing the amount of suppressive regulatory T cells (Tregs), inducing caspase-dependent apoptosis of T cells, and skewing T cells towards exhaustion, to ensure they circumvent the immune response [2]. Additionally, the presence of CD70 on cancer stem cells is a predictive marker for metastasis and poor prognosis [8]. Exploiting CD70-targeting in cancer patients could help eliminate the CD70-expressing cancer cell populations and abrogate the tumor-promoting mechanisms by the CD70-CD27 signaling axis, both in the early stage and advanced disease. Combinatorial approaches with anti-CD70 targeting therapies have proven their potential in both preclinical and clinical settings, using antibody-mediated therapy, chemotherapy, and Chimeric Antigen Receptor (CAR)-T cell therapy [1]. 

 

References:

1. Flieswasser, T., Van den Eynde, A., Van Audenaerde, J. et al. 2022. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res 41, 12.
2. Jacobs, J. et al. 2015. CD70: An emerging target in cancer immunotherapy. Pharmacol Ther 155, 1-10.
3. Buchan S.L, et al. 2018. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 131(1):39-48.
4. Sanborn RE, et al., 2022. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer. 10(8):e005147.
5. Starzer AM, Berghoff AS., 2020. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 4 (Suppl 3):e000629.
6. Vitale LA, et al., 2012. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res. 18(14):3812-21
7. Jacobs, J. et al. 2018. Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation. Oncoimmunology 7, e1440167.
8. Liu, L. et al. 2018. Breast cancer stem cells characterized by CD70 expression preferentially metastasize to the lungs. Breast Cancer 25, 706-716.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty